Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × elotuzumab × Plasma cell × Clear all

Phase

Phase 2 23 Phase 3 11 Phase 1 7 Phase 1/2 6 Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Cyclophosphamide 8 fludarabine 6 Dexamethasone 6 Bortezomib 5 Lenalidomide 4 Granulocyte Colony-Stimulating Factor 4 68Ga-pentixafor 4 Melphalan 3 Filgrastim 3 Fluorodeoxyglucose F18 2 tocilizumab 1 ruxolitinib 1 pomalidomide 1 pembrolizumab 1 methyl prednisolonate 1 ioversol 1 inebilizumab 1 iberdomide 1 fludarabine phosphate 1 eltrombopag 1 elotuzumab 1 carfilzomib 1 blinatumomab 1 Thalidomide 1 Tacrolimus 1 Sirolimus 1 Simvastatin 1 Prochlorperazine 1 Positron-Emission Tomography 1 Pemetrexed 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05560399 2026-01-02

CC-220

Icahn School of Medicine at Mount Sinai

Phase EARLY_PHASE1 Active not recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡